相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma
Li Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases
Sydney Dubois et al.
CLINICAL CANCER RESEARCH (2017)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma
Robert N. Booher et al.
CANCER RESEARCH (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia
B. T. Gaudette et al.
ONCOGENE (2016)
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice
G. Knittel et al.
BLOOD (2016)
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang et al.
BLOOD (2016)
FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science
Alvin C. Ma et al.
HUMAN GENE THERAPY (2016)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Esteban Braggio et al.
CLINICAL CANCER RESEARCH (2015)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
Tumor Necrosis Factor (TNF)-α Induction of CXCL10 in Endothelial Cells Requires Protein Arginine Methyltransferase 5 (PRMT5)-mediated Nuclear Factor (NF)-κB p65 Methylation
Daniel P. Harris et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance
James Q. Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma
C. Fernandez-Rodriguez et al.
LEUKEMIA (2014)
MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenstrom's Macroglobulinemia
O. Landgren et al.
LEUKEMIA (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells
Marilyn Giordano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
S. M. Ansell et al.
BLOOD CANCER JOURNAL (2014)
Resolution of thrombocytopenia with JAK2 mutation in a patient with Gaucher disease
Dominick Amato et al.
BLOOD (2013)
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stephanie Poulain et al.
BLOOD (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappa B
Stuart A. Rushworth et al.
CELLULAR SIGNALLING (2013)
Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Xin Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MyD88 and its divergent toll in carcinogenesis
Rosalba Salcedo et al.
TRENDS IN IMMUNOLOGY (2013)
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients
Stephen M. Ansell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
Lucy S. Hodge et al.
BLOOD (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A20: linking a complex regulator of ubiquitylation to immunity and human disease
Averil Ma et al.
NATURE REVIEWS IMMUNOLOGY (2012)
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice
Yuanyuan Chu et al.
BLOOD (2011)
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1
Lucy S. Hodge et al.
BLOOD (2011)
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
Sherine F. Elsawa et al.
BLOOD (2011)
High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
Z. L. Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
The Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival and Prevents Autoimmunity
Rita M. Tavares et al.
IMMUNITY (2010)
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Nathalie A. Johnson et al.
BLOOD (2009)
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia
Esteban Braggio et al.
CANCER RESEARCH (2009)
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Roland Schmitz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Frequent inactivation of A20 in B-cell lymphomas
Motohiro Kato et al.
NATURE (2009)
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology
Lars Vereecke et al.
TRENDS IN IMMUNOLOGY (2009)
Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis
Toshihiro Nanki et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
Lloyd T. Lam et al.
BLOOD (2008)
Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma
A. Nacinovic Duletic et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2008)
Bcl-2 family proteins and cancer
K. W. Yip et al.
ONCOGENE (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Wee J. Chng et al.
BLOOD (2006)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
